Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT II
Walter Reinisch(Medical University of Vienna), Séverine Vermeire(KU Leuven), Maria Kłopocka(Nicolaus Copernicus University), Dino Tarabar(Military Medical Academy), Caleb Bliss(Takeda (United States)), William J. Sandborn(University of San Diego), Martina Goetsch(Pfizer (United States)), Tomáš Vaňásek, Fabio Cataldi(Pfizer (United States)), Silvio Danese(IRCCS Ospedale San Raffaele), Xavier Hébuterne(Université Côte d'Azur), Paul Hellstern(Clinical Research Atlanta), Miles Sparrow(Alfred Health), Joo Sung Kim(National University College), Charu Gupta(Cytel (United States)), Kenneth J. Gorelick, Miloš Greguš, Michael Hoy(Takeda (United States))
Cited by 34
Related Papers
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k
Crohn's disease
|The Lancet|2012|2.1k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
Serious Infections and Mortality in Association With Therapies for Crohn’s Disease: TREAT Registry
|Clinical Gastroenterology and Hepatology|2006|906